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Abstract
Tissue factor, the primary initiator of the coagulation cascade,
maintains vascular integrity in response to injury. It is now
recognised that, in addition to the role as a procoagulant activator,
tissue factor participates in many tumour-related processes that
contribute to malignant disease progression. The present review
details the recent evidence supporting a role for tissue factor in
tumour haemostasis, angiogenesis, metastasis and malignant cell
survival. Furthermore, future research directions are discussed that
may enhance our understanding of the role and regulation of this
protein, which could ultimately lead to the innovative design and
development of new anticancer therapies.
Introduction
Angiogenesis, the development of new blood vessels from
the existing vasculature, and haemostasis, the coagulation
cascade leading to clot formation, are among the most
consistent host responses associated with cancer. Tissue
factor (TF) normally safeguards the vascular integrity of
tissues by initiating the coagulation cascade following vessel
injury. Hypercoagulability is exhibited by most cancer patients
and contributes to the pathogenesis of tumour growth and
metastasis by promoting angiogenesis. Haemostasis and
angiogenesis are therefore interrelated processes with
important implications for cancer therapy.
TF, similar to a number of haemostatic proteins, participates
in many tumour-related processes, including tumour angio-
genesis, metastasis, hypercoagulability and tumour cell survival;
processes that all contribute to malignant disease progression.
The molecular mechanisms responsible for the actions of TF are
only just beginning to be elucidated, but it is thought that they
occur by the action of intracellular signalling, resulting in gene
transcription and subsequent protein synthesis.
Tissue factor
TF – also known as coagulation factor III, thromboplastin, or
CD142 – is a 47 kDa transmembrane glycoprotein first
cloned independently by four different groups in 1987 [1-4].
The human TF gene spans 12.4 kbp, has six exons and is
located on chromosome 1, p21–p22. The TF protein consists
of a 219-amino-acid extracellular domain, a 23-amino-acid
transmembrane segment and a 21-amino-acid cytoplasmic
tail that does not bear significant homology with other
proteins [5]. In silico studies have resulted in TF being classi-
fied as a member of the class II cytokine/haematopoietic
growth factor family [6]. The extracellular domain of TF
contains factor VII/activated factor VII (FVIIa) binding sites,
but the transmembrane domain plays a crucial role in
anchoring the TF–FVIIa complex to the cell surface in addition
to complete expression of the procoagulant activity [7].
TF gene expression is complex and is regulated by a number
of transcription factors that may be sensitive to hypoxia or
anoxia, including activator protein (AP-1), nuclear factor-κB
(NF-κB), Sp-1 and early growth response gene-1 (Egr-1)
[8,9]. In addition, heparanase and platelet endothelial cell
adhesion molecule 1 both participate in the regulation of TF
gene expression (via activation of the p38 signalling pathway)
[10,11].
Although TF expression can be transiently upregulated in
monocytes or macrophages and endothelial cells (ECs) by
growth factors and cytokines, vascular ECs and intravascular
cells do not express TF in normal physiological situations.
Constitutive TF expression is restricted to subendothelial
cells (such as pericytes, smooth muscle cells and fibroblasts)
that only interact with blood when vascular integrity is
compromised [12]. However, it is clear that during
tumourigenesis, this strict regulation of TF expression is lost.
Upregulation of TF protein by tumour cells and associated
stromal cells has been well documented in breast cancer and
other malignant tumours [13-17]. TF is now known to exist in
several locations: in association with cells (intracellular or
surface location) and within the circulation, either associated
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with microparticles [18] or in a free, soluble form [19,20]. TF-
expressing microparticles are membrane vesicles derived
from haematopoietic cells (for example, monocytes and
platelets) that play a putative role in haemostasis activation in
cancer patients [21,22].
Cryptic TF refers to the part of the cellular TF pool that is
noncoagulant but retains functional cell signalling. Cryptic TF
contains unpaired cysteine thiols and activation involves the
formation of the disulphide bond Cys186–Cys209 [23].
Extracellular protein disulphide isomerase has been proposed
to target this disulphide bond, inactivating the procoagulant
activity of TF [24] while enhancing TF coagulant activity on
microparticles shed from cells [25]. Protein disulphide
isomerase has therefore been suggested to facilitate a
dynamic and reversible switch (conformational change)
between two distinct functional TF species: one that initiates
coagulation, and an encrypted form that does not – this
theory, however, is currently controversial [26].
In normal physiological conditions, initiation of the extrinsic
coagulation pathway occurs when TF is exposed to the
bloodstream, either following damage to the vascular system
integrity or upon activation of monocytes or ECs. FVIIa then
binds to TF on the cell surface. Sequential downstream
activation of haemostatic protease complexes leads to the
generation of thrombin, with subsequent platelet activation
and the formation of a fibrin clot that restores vessel integrity
(Figure 1) (reviewed in [27]). There is now increasing
evidence that, in addition to initiating haemostasis, binding of
FVIIa to TF directly cleaves protease-activated receptor
(PAR)-2 and results in phosphorylation of the TF cytoplasmic
domain. This subsequently inhibits the negative regulatory
control of PAR-2-mediated signalling, thereby promoting
angiogenesis (Figure 2) [28-30].
Tissue factor and tumour haemostasis
Many cancer patients display a hypercoagulable state leading
to frequent serious complications, such as thromboembolism
and haemorrhage. Moreover, the risk of tumour-associated
hypercoagulability is compounded by the effects of chemo-
therapy and radiotherapy on the coagulation cascade. The
annual incidence of venous thromboembolism in patients
receiving chemotherapy is estimated to be 11% and is
increased two-threefold with hormone therapies, such as
tamoxifen, currently used to treat breast carcinomas [31]. In
contrast to standard chemotherapeutic agents, antiangio-
genic agents generally elicit few toxic side effects. An
unexpected high incidence of both arterial and venous
thrombosis has been reported, however, in a number of
clinical trials in which patients received both antiangiogenic
agents and standard chemotherapy [32-34].
The specific mechanisms that can cause exacerbation of
prothrombotic events in cancer patients in response to these
combination therapies are unknown, but are likely to be
multifactorial and to involve the two major opposing
influences that control haemostasis: TF and tissue factor
pathway inhibitor (TFPI; an endogenous inhibitor of TF-
induced coagulation [35]). The vascular endothelial growth
factor (VEGF) receptor-2 inhibitor SU541 in combination with
Figure 1
Tissue factor is the primary initiator of the coagulation cascade. In
normal physiological conditions, following vessel damage or trauma,
tissue factor (TF) forms a complex with activated factor VII (FVIIa) in
the presence of calcium ions on an appropriate phospholipid
membrane, and allosterically enhances the enzyme activity of this
protease to catalyse the activation of factor X (FX) to FXa. Generation
of FXa by the TF–FVIIa complex triggers the proteolytic conversion of
prothrombin (factor II) to thrombin (activated factor II [FIIa]). This key
step in the coagulation cascade is effected by the catalytic activity of
the prothrombinase complex, which consists of FXa and the
nonenzymatic cofactor activated factor V (FVa) in a 1:1 stoichiometric
complex. The resulting burst in thrombin activity activates localised
platelets and catalyses the conversion of circulating fibrinogen into an
insoluble fibrin clot, thereby restoring vessel integrity.Page 3 of 10
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high doses of chemotherapeutic drugs (especially
gemcitabine and cisplatin) recently triggered a procoagulant
conversion of ECs in vitro (as measured by dramatic
increases in their surface TFPI expression (ie, the coagulation
index). In contrast, low (metronomic) concentrations of the
agents significantly attenuated the coagulation index increase
induced by these drugs, suggesting that use of low-dose
chemotherapy regimens (rather than traditional maximum-
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Figure 2
Tissue factor-induced protease-activated receptor 2 signalling. (a) When the cytoplasmic domain is nonphosphorylated, tissue factor (TF) exerts a
negative regulatory control on protease-activated receptor (PAR)-2 and inhibits signalling. (b) Binding of activated factor VII (FVIIa) to TF results in
proteolytic cleavage of PAR-2 and phosphorylation of the cytoplasmic domain of TF via activation of phosphatidylcholine-specific phospholipase C
(PC-PLC) and protein kinase C (PKC) alpha. Phosphorylation releases the negative regulatory control of PAR-2-mediated signalling, resulting in
activation of several mitogen-activated protein kinase (MAPK) pathways and subsequent gene transcription. Phosphatidylinositol 3-kinase (PI3K)
and Rac1 activation also constitute important signal transduction cascades, mainly related to antiapoptotic and migration processes. The
constitutive association of α3β1 integrin with aggressive breast cancer cells (for example, MDA-MB-231 cells) implies that tumour cells have lost
the ability to sense extracellular gradients of coagulation proteases and constitutively couple TF and integrin signalling. Although the precise
mechanism for this coupling is unknown, it may play a role in tumour cell invasiveness. The overall activation of these signalling pathways is
responsible for the induction of angiogenesis, malignant cell survival and metastasis, resulting in tumour growth and disease progression. BTCM,
breast tumour cell membrane; Cyr61, cysteine-rich angiogenic inducer 61; CTGF, connective tissue growth factor; EC, endothelial cell; Egr-1, early
growth response gene 1; ERK, extracellular signal-related kinase; JNK, c-jun N-terminal kinase; PKB, protein kinase B; TSP, thrombospondin;
uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor.tolerated dose regimens) might reduce the incidence of
adverse clotting events associated with antiangiogenic/
chemotherapy combination therapies [35].
The pathogenesis of a systemic hypercoagulable state is
complex, but principally relates to the procoagulant
properties of tumour cells, tumour-associated ECs and host
inflammatory cells, in addition to the activation and adhesive
interactions of these cells. In particular, upregulation of TF
plays a key role [36]. TF expression is an independent
predictive factor of venous thromboembolism development in
ovarian cancer [37] and is associated with venous
thromboembolism in pancreatic cancer [38]. Furthermore, the
quantity of TF+ microparticles in platelets significantly
correlates with plasma D-dimer levels (a marker that strongly
predicts venous thromboembolism events in cancer patients)
[21] and appears to predict a propensity to develop venous
thromboembolism in malignant disease [22]. This evidence
suggests that TF+ microparticles play a role in the hyper-
coagulable state of many cancer patients.
In human breast cancer cell lines, clotting assays have
demonstrated that the rate of clot formation is factor VII
dependent and that it is completely inhibited by an anti-TF
monoclonal antibody, indicating that TF is the only significant
procoagulant present in these cancer cells [39]. Furthermore,
tumour hypoxia and loss of the phosphatase and tensin
homolog (mutated in multiple advanced cancers-1 (PTEN)
tumour suppressor gene appears to cooperate in
upregulating TF expression and increasing the procoagulant
activity of malignant glioma cells [40]. Experiments by Yu and
colleagues in 2005 suggested a genetic cause for both local
and systemic hypercoagulability [41]. TF expression in
colorectal cancer cells in vitro was controlled by the
activation of K-ras oncogene and the inactivation of p53
tumour suppressor gene, in a manner dependent on mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase (PI3K). Furthermore, upregulation of TF in tumour cells
led to systemic TF release, demonstrating that K-ras and p53
influence not only cell surface TF expression, but also the
total amount of TF procoagulant activity released from cancer
cells into their local microenvironment and the circulation
[41]. It has yet to be demonstrated whether K-ras and p53
are involved in TF upregulation in breast cancer.
Bogdanov and colleagues were the first to show that
alternatively spliced TF mRNA, lacking exon 5, expresses a
protein [42]. This alternatively spliced TF mRNA has been
found in monocytes, ECs and cancer cells [20,43,44],
although at much lower levels than the fully spliced TF mRNA.
The procoagulant activity of alternatively spliced TF is
currently controversial; some reports have shown a coagulant
function [20], while other studies have not [19]. Clearly,
further studies are needed to clarify the functional
significance of alternatively spliced TF and the role it plays in
tumour haemostasis.
Tissue factor and tumour angiogenesis
Since the work of Judah Folkman in the 1970s, it is now
widely accepted that angiogenesis is essential for tumour
growth since tumours cannot grow beyond 2 mm3 without
developing a new vasculature [45]. TF can contribute to
angiogenesis by different pathways: indirectly, via clotting-
dependent mechanisms or by regulating the angiogenic
properties of tumour cells by altering the production of
growth regulatory molecules that act on vascular ECs; or
directly, by clotting-independent mechanisms.
Indirect regulation of angiogenesis
Clotting-dependent induction of tumour angiogenesis is
primarily mediated by TF-induced generation of thrombin and
the subsequent deposition of cross-linked fibrin, which
provides a provisional pro-angiogenic matrix that facilitates
blood vessel infiltration [27]. Activation of coagulation may
also indirectly support angiogenesis by releasing pro-
angiogenic factors from the α-granules of activated platelets
and generating additional angiogenic pathways that are
dependent on activated factor X (FXa), thrombin, and the G
protein-coupled PARs (PAR-1–PAR-4), such as thrombin
signalling through PAR-1 on ECs [46].
Experiments conducted by Zhang and colleagues in 1994
provided the first in vivo evidence that TF could regulate
angiogenesis by altering the expression of angiogenic
molecules (by a mechanism distinct from activation of the
coagulation system). Overexpression of TF in fibrosarcoma
[47], in gastric cancer cells [48] and in melanoma cells [12]
enhances tumour growth by diminishing the transcription of
antiangiogenic thrombospondins and/or by increasing the
transcription of pro-angiogenic VEGF. Although it is still
controversial whether thrombospondins are directly regulated
by TF overexpression in tumour cells [41,47], the cytoplasmic
domain of TF appears essential for the production of VEGF in
human gastric cancer [48] and melanoma [12] cells. In a
positive feedback mechanism, TF induces upregulation of
VEGF on tumour cells, further increasing TF expression [47].
A significant relationship between TF expression and micro-
vessel density (a surrogate marker of angiogenesis) exists in
breast cancer (Bluff JE, Menakuru SR, Cross SS, Brown NJ,
Reed MWR, Staton CA, manuscript in preparation) and other
cancers [38]. Furthermore, the significant correlation
between TF and VEGF in breast cancer [15], the
colocalisation of TF and VEGF in breast cancer cells [15],
and the correlation of increased TF, VEGF and microvessel
density with disease progression in breast carcinoma [14] all
provide further evidence that TF may modify the angiogenic
properties of tumour cells by altering the production of
growth regulatory molecules that act on the endothelium.
Direct regulation of angiogenesis
In addition to the indirect role that TF plays in tumour
angiogenesis, an intracellular function of TF has now been
hypothesised. Mice lacking TF die in utero (between embry-
Breast Cancer Research    Vol 10 No 2 Bluff et al.
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blood from both extraembryonic and embryonic vessels [49].
Furthermore, specific inhibitors to the TF–FVIIa–FXa complex
and to FXa alone demonstrate that the angiogenic process is
dependent on FVIIa but not on FXa [50]. Angiogenesis
therefore appears to be dependent on TF–FVIIa intracellular
function.
The clotting-independent pathway of TF-induced tumour
angiogenesis has been characterised primarily via PARs.
Although thrombin cleaves PAR-1, PAR-3 and PAR-4,
proteases such as FXa and the TF–FVIIa complex can
activate PAR-2. PAR-1 can also be cleaved and activated by
FVIIa, FXa, plasmin, activated protein C and matrix metallo-
proteinase 1 (reviewed in [51]). Multiple proteases can
clearly cleave and activate these receptors; thus, the
particular PAR and protease that function in a specific cellular
setting remain largely undefined.
TF–FVIIa signalling via PAR-2 was recently shown to play a
crucial role in breast tumour growth in a murine orthotopic
breast cancer model [28]. Additionally, angiogenesis mediated
by TF–FVIIa signalling has been demonstrated to be
regulated via PAR-2 signalling, tightly controlled by the TF
cytoplasmic domain (Figure 2) [29,30]. Genetic deletion of
the TF cytoplasmic domain resulted in both accelerated
physiological and pathological angiogenesis in mice. Loss of
negative regulatory control by the TF cytoplasmic domain is
therefore a pathway by which pro-angiogenic signalling of
PAR-2 can be turned on. Interestingly, platelet-derived
growth factor BB synergises with the enhanced PAR-2-
dependent angiogenesis observed in mice that lack the TF
cytoplasmic domain. Therefore it may be possible to target
deregulated TF cytoplasmic domain signalling to suppress
pathological PAR-2 and platelet-derived growth factor-
dependent angiogenesis, without interfering with the physio-
logical vascular functions of platelet-derived growth factor [30].
Furthermore, Ahamed and Ruf demonstrated that PAR-2
signalling specifically targets the TF cytoplasmic domain by
inducing TF phosphorylation at multiple serine residues [52].
Protein kinase C-dependent phosphorylation of Ser253
enhances subsequent Ser258 phosphorylation by a proline-
directed kinase. Thio-ester modification of the cytoplasmic
cysteine, however, counteracts TF phosphorylation [53].
PAR-2 expression and changes in the palmitoylation status of
TF therefore emerge as key regulators of cytoplasmic domain
phosphorylation. Although the ternary TF–FVIIa–FXa complex
similarly activates PAR-1 or PAR-2 (based on efficiency of
PAR internalisation and extracellular-signal related kinase
phosphorylation), it is PAR-2 signalling not PAR-1 signalling
that leads to prolonged protein kinase C alpha activation and
downstream TF cytoplasmic domain phosphorylation. Activa-
tion of phosphatidylcholine-specific phospholipase C up-
stream of protein kinase C alpha accounts for this unique
signalling response following PAR-2 activation [52].
The proteolytic activity of the TF–FVIIa complex induces
activation of various MAPK family members – such as
p42/p44 MAPK, p38 MAPK and c-jun N-terminal kinase –
which, at least in some cell types, form parts of the signalling
cassettes together with Src-like kinases and the lipid
protein/phosphatidylinositol 3-kinase [54]. Interestingly,
inhibition of the MAPK pathway was shown to significantly
prevent VEGF-driven upregulation of TF on ECs, indicating
the critical role of MAPK activation on TF production [55]. In
contrast, negative regulation of TF production has been
shown to occur via activation of the phosphatidylinositol 3-
kinase/Akt pathway [41,55]. In combination, these
experiments suggest that upregulated TF expression on ECs
may be the result of diminished phosphatidylinositol 3-kinase
activity or the result of an increase in MAPK activity.
Although the physiological relevance of TF–FVIIa-induced
activation of MAPK is not fully understood, the MAPK family
has been increasingly associated with cell proliferation,
suggesting that TF–FVIIa might contribute to the angiogenic
process simply by stimulating cell division. The mitogenic
capacity of TF–FVIIa remains disputable, however, and a more
probable mechanism involves the production of angiogenesis-
stimulating proteins. MAPK are well-known mediators of gene
transcription via the phosphorylation of transcription factors.
Exposure of TF-expressing cells (invasive breast cancer cells,
fibroblasts, pancreatic tumour cells and keratinocytes) to
FVIIa led to increased gene expression of VEGF [56,57],
urokinase-type plasminogen activator receptor [58], early
growth response gene 1 [59], IL-8 [56,60], cysteine-rich
angiogenic inducer 61 and connective tissue growth factor
[56]. These genes encode proteins that function either as
growth factors, as inducers of angiogenesis or as extra-
cellular matrix signalling proteins that facilitate the process of
new vessel development or regulate a myriad of cellular
functions, such as cell adhesion, proliferation and migration,
which are essential for tumour angiogenesis and metastasis.
PAR-2 also activates Rac and recruits a β-arrestin scaffolding
complex for extracellular signal-related kinase localisation,
thus promoting cell motility [61]. Additionally, the initiation of
TF–FVIIa signalling is further complicated by activation of
epidermal growth factor receptor with subsequent phos-
phorylation of the epidermal growth factor receptor cyto-
plasmic domain [62].
Tissue factor and tumour metastasis
Metastasis is the result of multiple pathways acting in concert
to provide tumour cells with the capacity to migrate, to gain
access to the bloodstream or lymphatic vessels, and to
ultimately home to distant sites. It is now clear that these
processes are highly dependent on components of the blood
coagulation cascade, such as thrombin [63,64]. Moreover, it
has been shown that TF supports metastasis through a
fibrin(ogen)-dependent and platelet-dependent restriction in
natural killer cell-mediated clearance of micrometastases [63].
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contrast to nonmetastatic breast carcinoma cells [65].
However, it is unclear how TF on tumour cells contributes to
tumour metastasis; the TF–FVIIa complex may play a direct
role and/or the downstream generation of active coagulation
factors may be implicated in this process. There is, however,
good evidence that TF–FVIIa signalling stimulates cell
motility. Experimental work has shown that extracellular
ligation of the TF molecule results in the specific interaction
of the cytoplasmic domain with actin-binding protein 280,
which supports cell adhesion and migration in in vitro assays
[66]. In fibroblasts, TF–FVIIa signalling enhanced platelet-
derived growth factor BB-stimulated migration, suggesting
signalling cross-talk between PARs and tyrosine kinase
receptors in this process [67].
PAR-1 expression is minimal or absent in benign and normal
breast tissue and noninvasive carcinoma, but thrombin
activation of PAR-1 has been implicated in tumour cell
growth, in invasion and metastasis of breast cancer and in
other human malignant diseases [64]. Little is known
regarding the role of tumour cell PAR-2 in this process.
Signalling of the TF–FVIIa–FXa complex, however, has been
shown to enhance the migration of breast cancer cells in
vitro, via a PAR-2-dependent mechanism [68]; and anti-
PAR-2 antibodies inhibit the indirect and promigratory effect
of IL-8 in breast carcinoma cells [60]. Furthermore, small
interfering RNA targeting PAR-1 and PAR-2 demonstrated
impaired migration of invasive breast cancer cells deficient in
PAR-2, but not deficient in PAR-1, once again demonstrating
the critical role for PAR-2 in breast cancer cell migration and
invasion [69].
The role of the TF cytoplasmic domain as a negative regulator
of chemotaxis has been supported by the recent observation
that TF expression in keratinocytes and melanoma cells
suppresses  α3β1-dependent migration on laminin 5. This
effect was reversed by PAR-2-dependent phosphorylation of
the TF cytoplasmic domain, demonstrating that phosphoryla-
tion regulates the function of TF in cell motility (Figure 2) [70].
Other reports have also indicated the mandatory function of
the cytoplasmic TF domain for cell migration of porcine aortic
ECs [71] and human bladder carcinoma cells, through the
activation of p38 and Rac1 [72]. Interestingly, TF has recently
been shown to be constitutively associated with α3β1 on
highly aggressive breast cancer cells (MDA-MB-231) [28],
although the precise mechanism for this coupling remains to
be elucidated.
TF expression correlates strongly with metastatic potential in
many human tumours, and the expression of functional TF in
in vivo metastasis models has confirmed that TF plays an
important role in this process [73-76]. The metastatic
potential of two subsets of melanoma cells, expressing high
levels and low levels of human TF, was compared by
intravenous injection of the tumour cells into severe
combined immunodeficiency mice. Metastatic lung tumours
were detected in 86% of the mice injected with the high-TF-
expressing lines, but in only 5% of the mice injected with the
low-TF-expressing lines, indicating that a high TF level
promotes lung metastasis of human melanoma in vivo [75]. A
blocking anti-TF monoclonal antibody and Fab fragments
thereof significantly inhibited the growth of pulmonary
metastases in this model [76], dependent on both signalling
of the TF cytoplasmic domain [75,77] and on the extracellular
proteolytic activity of the active TF–FVIIa complex [75].
Moreover, PAR-1 enhanced the metastatic potential of TF in
this model [78]. More recently, in a similar model of
metastasis, small interfering RNAs targeting TF on melanoma
cells inhibited melanoma cell colonisation of the lung [74]; it
has since been proposed that silencing of tissue factor
pathway inhibitor 2 may be involved in tumour cell metastasis
[79]. A humanised anti-TF monoclonal antibody (CNTO 859)
also inhibited experimental lung metastasis of invasive breast
cancer cells (MDA-MB-231), by over 99% [73], suggesting a
role for TF in breast cancer as well as melanoma cell
metastasis.
Tissue factor and tumour cell survival
It is possible that defects in apoptosis or activation of
antiapoptotic pathways promote tumour growth and survival,
which may be linked to tumour metastasis. Indeed, resistance
to apoptosis is a key factor in the survival of malignant cells
[51]. FVIIa is known to induce the activation of both P42/44
MAPK and protein kinase B signalling – pathways known to
inhibit apoptosis [80]. The effect of TF–FVIIa-mediated
signalling on apoptosis has recently been investigated in a
human breast cancer cell line (MCF-7) that had been trans-
fected to express TF [81]. The formation of the TF–FVIIa–FXa
complex prevented apoptosis in these cells by a thrombin-
independent pathway. Moreover, the antiapoptotic effect of
this signalling pathway involved phosphorylation of both
p44/42 MAPK and protein kinase B/Akt, and may be
mediated, in part, by an increase in the antiapoptotic protein
survivin. Additional studies have demonstrated that FVIIa
appears to be capable of inducing cell survival in serum-
deprived baby hamster kidney and Chinese hamster ovary
cells that overexpressed TF [82]. Furthermore, FVIIa inhibits
apoptosis induced by the loss of adhesion [83], and TF–FVIIa
signalling can induce cell survival through STAT5-dependent
BclxL production and Jak2-dependent activation of protein
kinase B [84].
It has been hypothesised that the expression of TF by
disseminated tumour cells confers protection against immune
recognition and cytotoxicity. When challenged with peripheral
blood mononuclear cells, TF-expressing colon carcinoma
cells (HT29) partially evaded cellular cytotoxicity by approxi-
mately 40% and this protective function was dependent on
the cytoplasmic domain of TF [85]. TF may therefore be
capable of promoting immune evasion in tumour cells, which
could lead to increased cell survival and metastasis of cancer
Breast Cancer Research    Vol 10 No 2 Bluff et al.
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is limited to cells transfected to overexpress TF. The anti-
apoptotic effect of TF–FVIIa signalling in tumour and/or
associated stromal cells has therefore not yet been
confirmed.
Future directions for tissue factor research
The direct targeting of TF with, for example, monoclonal anti-
bodies or inactivating peptides has already been demon-
strated efficacious in several models in vivo [69]. Moreover,
inhibition of various procoagulant and TF signalling effects
using antagonists (for example, tissue factor pathway
inhibitor) [86], inducing selective intratumoral thrombosis
(tumour infarction) [87] or inducing immune attack [88] are
currently being explored. One of the major anticipated
adverse effects of these approaches in humans are problems
associated with the haemostatic system. Although a recent
phase I clinical trial with a monoclonal antibody to TF
reported no major bleeding events, the frequency of minor
haemorrhage increased in a dose-dependent manner,
characterised by oral mucosal bleeding, spontaneous tongue
haematomas and cutaneous bleeding [89]. Interestingly, most
animal models have reported no apparent side effects using
different anti-TF approaches, perhaps reflecting the focus on
agents that act locally – for example, strategies specifically
targeted to TF expressed within tumours – thereby causing
minimal disturbance of systemic haemostasis. Phase I direct
TF-targeting clinical studies are now in progress, but many
important questions remain unanswered. What causes the
upregulation of TF in cancer cells, with the subsequent
increase in their malignancy? Do oncogene-directed
therapies impact on expression of TF in vivo and do TF-
targeting agents synergise with oncogene-targeting agents,
antiangiogenics or anticancer chemotherapy?
Broad generalisations regarding the role of TF in cancer
progression and metastasis may be premature. This is likely
to depend on the biological context such as cell, tissue and
disease type, as well as on the expression of other genes
related to the malignant process; this clearly warrants more
extensive and thorough investigation.
There is still no direct evidence that TF, as a true receptor,
induces cell signalling via the cytoplasmic tail, and an
increasing number of studies suggest a direct role for TF and
FVIIa in TF-mediated oncogenic processes through the
activation of signal transduction pathways via the proteolytic
cleavage of PAR-2. However, it is largely unclear which other
cell membrane components, such as integrins, proteoglycans
and growth factor receptors, may also be involved in trans-
mitting or regulating TF–FVIIa signalling. Analysis of other
potential cell surface receptors mediating TF–FVIIa signalling
and investigations into how the spatial organisation of
participating signalling components regulates TF–FVIIa
signalling are important areas requiring further study.
Characterisation of ligand binding to the phosphorylated and
nonphosphorylated TF cytoplasmic domain will be
instrumental in understanding the signalling complexes that
associate with TF. It has been proposed that epitopes unique
to the TF–FVIIa complex may allow specific targeting of
TF–FVIIa signalling associated with cancer progression,
without compromising haemostasis [23-25,28].
Versteeg and colleagues recently employed a unique pair of
isotype-matched anti-TF antibodies that specifically block
either direct TF–FVIIa signalling (mAb 10H10) or coagulation
(mAb 5G9). These authors showed that mAb 10H10 (and
also inhibition of PAR-2 signalling) was effective in suppres-
sing aggressive human breast cancer cell growth in both
murine subcutaneous and orthotopic models, with minimal
effects on TF coagulant function [28]. What is unclear,
however, is whether the possibility exists in vivo that TF–FVIIa
is active without concomitant FXa generation and FXa/
thrombin-mediated PAR signalling; this approach therefore
needs validation.
Detailed investigations into the mechanisms of TF-induced
signal transduction and the regulation and function of TF will
therefore be instrumental for devising rational therapy aimed
at inhibiting TF-dependent tumour vascularisation, hyper-
coagulability and metastasis. Furthermore, TF is quantifiable
in plasma and serum, and tumour cells are known to shed TF
into the circulation. Furthermore, TF is quantifiable in plasma
and serum and tumour cells are known to shed TF into the
circulation; clearly, more studies are required to evaluate
circulating TF (microparticles) as a diagnostic and/or prog-
nostic marker of tumour progression or pathological angio-
genesis in cancer.
Conclusion
Substantial evidence exists supporting a role for TF acting as
both a regulatory target and as an important mediator of
oncogenic processes, specifically tumour metastasis and
tumour-associated angiogenesis and hypercoagulability.
Furthermore, TF expression by cancer cells and tumour-
associated stromal cells, but not by benign tumours, makes
TF an attractive therapeutic target. Like most therapies, anti-
TF strategies may have their caveats – but preclinical studies
with TF-targeted cancer therapeutics have demonstrated
efficacy that may translate to the clinical setting, offering
renewed hope for the control of cancer growth and
metastasis. The development of specific inhibitors that
suppress TF–FVIIa signalling in pathological angiogenesis,
but not TF–FVIIa coagulant function, could provide oppor-
tunities to design specific drugs with therapeutic value for the
treatment of cancer. Furthermore, as TF–FVIIa is a
multitasking complex, numerous relevant potential targets for
therapeutic intervention have yet to be explored.
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